Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pompe disease
Biotech
Bayer ditches 1 AAV gene therapy from Pompe disease pair
Bayer has discontinued a phase 1-stage gene therapy for a rare disorder in favor of a similar candidate.
James Waldron
Mar 4, 2026 9:59am
Denali ph. 1 Pompe plans hit with clinical hold
Dec 4, 2025 11:52am
Roche pumps brakes in Pompe after assessing competition
Jul 25, 2024 6:32am
Crosswalk grabs compounds from abandoned Takeda, Codexis collab
Jul 2, 2024 9:55am
After FTC stalled Sanofi deal, Shionogi bags Maze's Pompe drug
May 10, 2024 5:02am
Sanofi CEO does not rule out future Pompe BD despite FTC moves
Jan 10, 2024 3:37pm